Kundu Reetu, Srinivasan Radhika, Dey Pranab, Gupta Nalini, Gupta Parikshaa, Rohilla Manish, Gupta Shruti, Bal Amanjit, Rajwanshi Arvind
Department of Cytology and Gynecological Pathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
J Cytol. 2021 Jan-Mar;38(1):1-7. doi: 10.4103/JOC.JOC_224_20. Epub 2021 Feb 17.
Recently, the Indian Academy of Cytologists (IAC) has published the guidelines for interpretation and reporting of serous effusions. Till date, there are no studies on its applicability.
The present study was carried out to assess the feasibility of applying the IAC reporting categories to effusions, determine the frequency, and provide an estimate of the risk of malignancy (ROM) for individual diagnostic categories.
All cases of serous effusion fluids reported in the year 2019 were retrieved from the archives and reassigned as per the IAC diagnostic categories. The clinical and histopathological follow-up information was obtained wherever possible.
A total of 1340 effusion samples were received from 1085 patients. There were 561 (51.7%) males and 524 (48.3%) females. Majority were pleural (1066, 79.5%), followed by peritoneal (187, 14%) and pericardial (87, 6.5%) effusions. The age ranged from 7 months to 92 years. There were 35 (2.6%) samples in category 1 (non-diagnostic), 954 (71.2%) in category 2 (benign), 17 (1.3%) in category 3 (atypical), 59 (4.4%) in category 4 (suspicious for malignancy) and 275 (20.5%) in category 5 (malignant). The estimated ROM in serous effusion samples was 20% for category 1, 16.7% for category 2, 50% for category 3, 94.4% for category 4 and 100% for category 5.
The categorization of serous effusion cytology samples as per the IAC diagnostic categories and as per the reporting format developed by the IAC is feasible and the management recommendations are mostly appropriate.
最近，印度细胞学家学会（IAC）发布了浆液性积液的解读和报告指南。迄今为止，尚无关于其适用性的研究。
开展本研究以评估将IAC报告类别应用于积液的可行性，确定频率，并对各个诊断类别给出恶性肿瘤风险（ROM）的估计值。
从档案中检索2019年报告的所有浆液性积液病例，并根据IAC诊断类别重新分类。尽可能获取临床和组织病理学随访信息。
共收到来自1085例患者的1340份积液样本。其中男性561例（51.7%），女性524例（48.3%）。多数为胸腔积液（1066例，79.5%），其次是腹腔积液（187例，14%）和心包积液（87例，6.5%）。年龄范围为7个月至92岁。1类（非诊断性）样本有35例（2.6%），2类（良性）954例（71.2%），3类（非典型）17例（1.3%），4类（可疑恶性）59例（4.4%），5类（恶性）275例（20.5%）。浆液性积液样本的估计ROM在1类中为20%，2类中为16.7%，3类中为50%，4类中为94.4%，5类中为100%。
按照IAC诊断类别以及IAC制定的报告格式对浆液性积液细胞学样本进行分类是可行的，且管理建议大多是合适的。
